Increased C-reactive Protein Levels during Short-term Hormone Replacement Therapy in Healthy Postmenopausal Women

Marchien W. van Baal; Peter Kenemans; Marius J. van der Mooren; Hilda Kessel; Jef J. Emeis; Coen D. A. Stehouwer

doi:10.1055/s-0037-1614600

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1999; 81(06): 925-928
DOI: 10.1055/s-0037-1614600

Letters to the Editor

Schattauer GmbH

Increased C-reactive Protein Levels during Short-term Hormone Replacement Therapy in Healthy Postmenopausal Women

Marchien W. van Baal

¹From the Project “Ageing Women” and the Institute for Cardiovascular Research-Vrije Universiteit (ICAR-VU), Departments of Obstetrics and Gynaecology, Leiden, The Netherlands

,

Peter Kenemans

¹From the Project “Ageing Women” and the Institute for Cardiovascular Research-Vrije Universiteit (ICAR-VU), Departments of Obstetrics and Gynaecology, Leiden, The Netherlands

,

Marius J. van der Mooren

¹From the Project “Ageing Women” and the Institute for Cardiovascular Research-Vrije Universiteit (ICAR-VU), Departments of Obstetrics and Gynaecology, Leiden, The Netherlands

,

Hilda Kessel

¹From the Project “Ageing Women” and the Institute for Cardiovascular Research-Vrije Universiteit (ICAR-VU), Departments of Obstetrics and Gynaecology, Leiden, The Netherlands

,

Jef J. Emeis

³Gaubius Laboratory, TNO-Prevention and Health, Leiden, The Netherlands

,

Coen D. A. Stehouwer

²Internal Medicine, University Hospital Vrije Universiteit, Amsterdam, and Leiden, The Netherlands

› Institutsangaben

Abstract

Summary

Objective: To study the short-term effect of unopposed oestradiol (E₂) and sequentially combined hormone replacement therapy (E₂ + P) on C-reactive protein (CRP) in healthy postmenopausal women. Design: Prospective, randomised, placebo-controlled 12-week study. Sixty healthy, normotensive, non-hysterectomised postmenopausal women received either placebo (N = 16) or daily 2 mg micronised oestradiol, either unopposed (N = 16, E₂ group) or sequentially combined with a progestagen on 14 days of each cycle (N = 28, E₂+P group). Data were collected at baseline and at 4 and 12 weeks. Results: CRP levels increased significantly during the 12 weeks in the E₂ and the E₂+P groups compared to placebo. No differences were found between the E₂ group and the E₂+P group [E₂ and E₂+P group together (N = 44) versus placebo: P = 0.01; E₂ versus E₂+P: P = 0.75]. To give a quantitative estimate of the increase, the median change calculated from baseline in both treatment groups together was +87% (P = 0.02) at 4 weeks, and +114% (P = 0.08) at 12 weeks, as compared to the placebo group. Conclusion: In healthy postmenopausal women, short-term treatment with E₂ or E₂+P was associated with a rapid rise in CRP concentrations. These observations raise the possibility that the increased risk of cardiovascular events is related to an initial increase in CRP levels after starting hormone replacement therapy.

Volltext

Referenzen

References
1 Ridker PM, Cushman M, Stampfer MJ, Tracy RM, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
2 Ridker PM, Buring JE, Shih J, Matias M, Henneken CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731-3.
3 Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-13.
4 Salomaa V, Rasi V, Pekkanen J, Vahtera E, Jauhiainen M, Vartiainen E, Ehnholm C, Tuomilehto J, Myllyla G. Association of hormone replacement therapy with hemostatic and other cardiovascular risk factors. The FINRISK Hemostasis Study. Arterioscler Thromb Vasc Biol 1995; 15: 1549-55.
5 Myrup B, de Maat M, Rossing P, Gram J, Kluft C, Jespersen J. Elevated fibrinogen and the relation to acute phase response in diabetic nephropathy. Thromb Haemost 1996; 81: 485-90.
6 Claus A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haemat 1957; 17: 237-46.
7 Yudkin PL, Stratton IM. How to deal with regression to the mean in intervention studies. Lancet 1996; 347: 241-3.
8 Scarabin PY, Alhencgelas M, Plubureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women – a randomized controlled trial. Arterioscler Thromb Vasc Biol 1997; 17: 3071-8.
9 Espeland MA, Marcovina SM, Miller V, Wood P, Wasilauskas C, Sherwin R, Schrott H, Bush TL. Effect of postmenopausal hormone therapy on lipo-protein(a) concentration. PEPI Investigators. Postmenopausal Estrogen/ Progestin Interventions. Circulation 1998; 97: 979-86.
10 Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawence JB, Shah AS, Anderson PW. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998; 279: 1445-51.
11 Van Baal WM, Kenemans P, Emeis JJ, Schalkwijk CG, Van der Mooren MJ, Vischer UM, Stehouwer CDA. Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women. Fertil Steril 1999; 71: 663-70.
12 Writing group for the estradiol clotting factors study Effects on haemostasis of hormone replacement therapy with transdermal and oral sequential medroxyprogesteron acetate: A 1-year, double-blind, placebo-controlled study. Thromb Haemost 1996; 75:: 476-80.
13 The writing group for the PEPI trial Effects of estrogen or estrogen/ progestin regimes on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Intervention (PEPI) trial. JAMA 1995; 273:: 199-208.
14 Haverkate F, Thompson SG, Pyke SM, Gallimore JR, Pepys MB.. Production of c-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997; 349:: 462-6.
15 de Maat MP, Pietersma A, Kofflard M, Sluiter W, Kluft C. Association of plasma fibrinogen levels with coronary artery disease, smoking and inflammatory markers. Atherosclerosis 1996; 121: 185-91.